Screener
Axsome Therapeutics AXSM Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's enterprise value?
- Axsome Therapeutics (AXSM) reported enterprise value of $8.56B in Q1 2026.
- How has Axsome Therapeutics's enterprise value changed year-over-year?
- Axsome Therapeutics's enterprise value increased by 52.9% year-over-year, from $5.6B to $8.56B.
- What is the long-term trend for Axsome Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Axsome Therapeutics's enterprise value has grown at a 25.6% compound annual growth rate (CAGR), from $2.92B to $9.1B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Axsome Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude